Focus Advisor Solutions LLC Acquires 17,571 Shares of Gilead Sciences, Inc. $GILD

Focus Advisor Solutions LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 17,571 shares of the biopharmaceutical company’s stock, valued at approximately $2,619,000.

Other institutional investors have also modified their holdings of the company. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences during the second quarter worth approximately $25,000. Kimelman & Baird LLC purchased a new position in Gilead Sciences in the 2nd quarter valued at $25,000. PFS Partners LLC lifted its holdings in Gilead Sciences by 101.1% in the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 96 shares in the last quarter. Laurel Wealth Advisors LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth $29,000. Finally, Wiser Advisor Group LLC acquired a new stake in Gilead Sciences during the 2nd quarter worth $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.1%

Shares of GILD opened at $166.33 on Friday. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $176.58. The company has a market capitalization of $206.30 billion, a PE ratio of -52.64 and a beta of 0.35. The stock has a fifty day simple moving average of $157.26 and a two-hundred day simple moving average of $142.46. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same quarter in the previous year, the firm earned $2.47 EPS. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, equities analysts forecast that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. Gilead Sciences’s payout ratio is -103.80%.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Scotiabank upped their target price on shares of Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a report on Friday, October 30th. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research report on Friday, October 30th. Needham & Company LLC set a $175.00 price target on shares of Gilead Sciences in a research report on Friday, October 30th. TD Cowen set a $175.00 price objective on shares of Gilead Sciences in a research note on Wednesday. Finally, Bank of America increased their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a report on Tuesday, October 20th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $171.63.

Read Our Latest Research Report on GILD

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $170.55, for a total value of $4,775,400.00. Following the transaction, the insider directly owned 110,684 shares in the company, valued at $18,877,156.20. The trade was a 20.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Keeley Cain Wettan sold 3,399 shares of the stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $164.11, for a total transaction of $557,809.89. Following the completion of the sale, the executive vice president directly owned 5,360 shares of the company’s stock, valued at approximately $879,629.60. This trade represents a 38.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 237,709 shares of company stock valued at $39,799,137. Company insiders own 0.30% of the company’s stock.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.